Improving Outcomes in Mantle Cell Lymphoma

Ann S. LaCasce, MD, MMSc


January 31, 2023

Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin lymphoma (NHL), accounting for 6% of NHL cases in the United States. There is no curative treatment for MCL, and the majority of patients will relapse after initial therapy, even after high-dose chemotherapy and stem cell transplant.

In recent years, Bruton tyrosine kinase (BTK) inhibitors have significantly improved life expectancy, more than doubling the overall survival in patients with relapsed or refractory disease. However, progression on BTK inhibitor therapy inevitably occurs in a subset of patients, and outcomes for these patients are extremely poor, resulting in a median overall survival of only 6-10 months.

In this ReCAP, Dr Ann LaCasce from the Dana-Farber Cancer Center in Boston, Massachusetts, reports on newly available therapies, such as CAR T-cell therapy with brexucabtagene autoleucel, for eligible patients whose MCL progresses after BTK inhibitor therapy. Recent clinical data have shown that more than half of the patients who received CAR T-cell therapy remain in remission at 2 years.

Dr LaCasce also discusses emerging therapies for patients with relapsed/refractory MCL who are not eligible for CAR T-cell therapy, including bispecific antibodies, antibody-drug conjugates, and noncovalent BTK inhibitors, all of which have shown promising early clinical trial results.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.